RankAlpha logo
Back to Rankings

MIRM

MirumC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
AZURE-1's positive Phase 3 result, the ATEBRIOZ approval and Q2 LIVMARLI sales of $128.7 million support multiple distinct growth avenues. Mirum raised 2026 net-product-sales guidance to $680 million–$700 million.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.7.
What can break
ATEBRIOZ launch access and uptake remain unproven; its approved FOP population is ultra-rare. Mirum/Incyte release
Momentum
19
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $94.00 · Bull $125.00 · Bear $59.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-27

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $153.43
Why
Momentum19 · Δ7d +8.8
Value41 · Δ7d -0.1
Sentiment73 · Δ7d -3.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta -3.7.

Contradictions & invalidation

  • • ATEBRIOZ launch access and uptake remain unproven; its approved FOP population is ultra-rare. Mirum/Incyte release
  • • AZURE-4 efficacy or safety may not replicate AZURE-1; brelovitug remains investigational. Mirum AZURE-1 release
  • • AZURE-4 could fail to replicate AZURE-1, ATEBRIOZ is launching into an ultra-rare population, and development spending remains substantial.

Catalyst clock

2026-09-28

Brelovitug Phase 3 AZURE-1 result

Lead driver: Sentiment · See AI snapshot
Momentum
19
8% active weight
Current posture
7d trendImproving
Δ7d
+8.8
Δ21d
-1.4
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
73
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.7
Δ21d
-14.8
Why this grade

Composite grade C. Momentum 18.6 / Value 40.6 / Sentiment 73.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method

B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$94.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$59.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$5.56B
Beta
0.49
Shares Out
64.93M
P/E (TTM) · Derived
-183.8
P/S (TTM)
8.28
P/FCF (TTM)
88.12
Rev YoY
+37.9%
EPS YoY
+799.7%
Gross Margin
+81.7%
Op Margin
-14.8%
Net Debt
-$63.88M
Current Ratio
2.86
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data